News in respiratory medicine

Česká verzia

Authors: Kristián Brat ^1,2,3; Martina Doubková ^1,3; Monika Bratová ^1,3; Nela Šťastná ^1,3; Jiří Wallenfels ⁴; Ivana Čierná Peterová ⁵
Authors place of work: Klinika nemocí plicních a tuberkulózy, Fakultní nemocnice Brno ¹; International Clinical Research Center, Fakultní nemocnice u svaté Anny, Brno ²; Lékařská fakulta Masarykovy Univerzity, Brno ³; Národní jednotka dohledu nad tuberkulózou, Fakultní nemocnice Bulovka, Praha ⁴; Plicní ambulance Brandýs nad Labem ⁵
Published in the journal: Vnitř Lék 2023; 69(5): 329-334
Category: News in...
doi: https://doi.org/10.36290/vnl.2023.064

Summary

Pneumology and phthisiology (respiratory medicine) has undergone dynamic development in the last two decades. The main focus of pulmonology in the past was care for patients with tuberculosis and pneumonia. Since then, respiratory medicine evolved and the current focus is on chronic pulmonary diseases, including chronic obstructive pulmonary disease, bronchial asthma, interstitial lung diseases, but also on acute lung conditions (e.g., pneumonia, pleural diseases, respiratory failure), pneumooncology or highly specialized care for rare lung diseases (e.g., cystic fibrosis, rare interstitial diseases). Bronchology, interventional pneumology and pulmonary function testing are also important components of respiratory medicine. The importance of respiratory medicine was apparent during the COVID-19 pandemic. In this article, we provide a brief overview of the most important news to the field of respiratory medicine in the year 2022, addressing the thematic areas of bronchology, cystic fibrosis, chronic obstructive pulmonary disease, asthma, interstitial lung diseases, pleural diseases, pneumooncology, tuberculosis and non-tuberculous mycobacteria.

Keywords:

tuberculosis – pneumology – bronchial asthma – chronic obstructive pulmonary disaese – interstitial lung disaeses – pneumooncology

Zdroje

Styrvoky K, Schwalk A, Pham D, et al. Shape-Sensing Robotic-Assisted Bronchoscopy with Concurrent use of Radial Endobronchial Ultrasound and Cone Beam Computed Tomography in the Evaluation of Pulmonary Lesions. Lung. 2022; 200(6):755-761.
WABIP Academy: WCBIP Congress 2022 Published Abstracts (Abstract 216). Kurman J, Wagh A, Benn B, Islam S. A comparison of single-use bronchoscopes & reusable bronchoscopes for interventional pulmonology applications. Cited: 16. 5. 2023. Available from: https://www.wabipacademy.com/publications/abstracts/wcbip2022/131-wcbip-congress- 2022-published-abstracts/file.
Pallenberg ST, Pust MM, Rosenboom I, et al. Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome. Microbiol Spectr. 2022; 10(5):e01454-22.
Doligalski CT, McKinzie CJ, Yang A, et al. Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients. Pharmacother J Hum Pharmacol Drug Ther. 2022;42(7):580-584.
Spoletini G, Gillgrass L, Pollard K, et al. Dose adjustments of Elexacaftor/Tezacaftor/Ivacaftor in response to mental health side effects in adults with cystic fibrosis. J Cyst Fibros. 2022;21(6):1061-1065.
Ishimaru D, Boudko D, Meleshkevitch EA, et al. Functional Rescue of CFTR by Aerosolized Delivery of Optimized CFTR mRNA Using ReCode-LNPs in Primary Human Bronchial Epithelial Cells Derived from Patients with Cystic Fibrosis. In: D109. AIRWAY OF INTEREST: EPITHELIAL AND SMOOTH MUSCLE FUNCTION IN HEALTH AND DISEASE. American Thoracic Society; 2022:A5488-A5488.
Piotrowski-Daspit AS, Barone C, Lin CY, et al. In vivo correction of cystic fibrosis mediated by PNA nanoparticles. Sci Adv. 2022;8(40):eabo0522.
Global strategy for the diagnosis, management and prevention of COPD; 2023. Navštíveno: 7. 5. 2023. Dostupné z: https://goldcopd.org/2023-gold-report-2/
Frazier WD, DaVanzo JE, Dobson A, et al. Early Initiation of non-invasive ventilation at home improves survival and reduces healthcare costs in COPD patients with chronic hypercapnic respiratory failure: A retrospective cohort study. Respir Med. 2022; 200:106920.
Brat K, Koblížek V. Stanovení prognózy pacienty s CHOPN – význam pro klinickou praxi a jak na to. Stud Pneumol Phthiseol. 2022;82(2):56-64.
McDonald VM, Gibson PG. Treatable traits in asthma: moving beyond diagnostic labels. Med J Aust. 2022;216(7):331-333.
Brusselle GG, Koppelman GH. Biologic Therapies for Severe Asthma. N Engl J Med. 2022;386(2):157-171.
Jendzjowsky N, Laing A, Malig M, et al. Long-term modulation of airway remodelling in severe asthma following bronchial thermoplasty. Eur Respir J. 2021;59(1):2100622.
Tyson L, Hardeman W, Marquette M, et al. A systematic review of the characteristics of interventions that promote physical activity in adults with asthma. J Health Psychol. 2022;27(12):2777-2796.
Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases. Lancet. 2022; 400(10354):769-786.
Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18-e47.
Raghu G, Remy-Jardin M, Ryerson CJ, et al. Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2020; 202(3):e36-e69. Erratum in: Am J Respir Crit Care Med. 2022;206(4):518.
Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021;58(6):2004079.
Brat K. Nové diagnostické a léčebné postupy u maligního pleurálního výpotku. Onkologie. 2023;17(1):16-21.
Lu P, Sun Y, Liang B, Yu L. Derivation and validation of a 18 F-FDG PET/CT scoring model to predict malignant pleural effusion. Nucl Med Commun. 2022;43(2):177-185.
Sundaralingam A, Bedawi EO, Harriss EK, et al. The Frequency, Risk Factors, and Management of Complications From Pleural Procedures. Chest. 2022;161(5):1407-1425.
Luengo-Fernandez R, Landeiro F, Hallifax R, et al. Cost-effectiveness of ambulatory care management of primary spontaneous pneumothorax: an open-label, randomised controlled trial. Thorax. 2022;77(9):913-918.
Herbst RS, Wu YL, John T, et al. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol. 2023;41(10):1830-1840.
Solomon BJ, Bauer TM, Mok TSK, et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med. 2023;11(4):354-366.
de Langen AJ, Johnson ML, Mazieres J, et al., CodeBreaK 200 Investigators. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. Lancet. 2023;401(10378):733-746.
Goldman JW, Dvorkin M, Chen Y, et al. CASPIAN investigators. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51-65.
Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375-386.
World Health Organization. Rapid communication: key changes to the treatment of drug-resistant tuberculosis. Cited: 6. 5. 2023. Available from: https://www.who.int/ publications/i/item/WHO-UCN-TB-2022-2
Günther G, Ruswa N, Keller PM. Drug-resistant tuberculosis: advances in diagnosis and management. Curr Opin Pulm Med. 2022;28(3):211-217.
Nyang‘wa BT, Berry C, Kazounis E, et al.; TB-PRACTECAL Study Collaborators. A 24Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2022; 387(25):2331-2343.
Conradie F, Bagdasaryan TR, Borisov S, et al.; ZeNix Trial Team. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. N Engl J Med. 2022;387(9):810-823.
Suska K, Amati F, Sotgiu G, et al. Nontuberculous mycobacteria infection and pulmonary disease in bronchiectasis. ERJ Open Res. 2022;8(4):00060-2022